CN112654353A - 用于治疗眼部疾病的方法和药物成分 - Google Patents

用于治疗眼部疾病的方法和药物成分 Download PDF

Info

Publication number
CN112654353A
CN112654353A CN201980054524.XA CN201980054524A CN112654353A CN 112654353 A CN112654353 A CN 112654353A CN 201980054524 A CN201980054524 A CN 201980054524A CN 112654353 A CN112654353 A CN 112654353A
Authority
CN
China
Prior art keywords
compound
subject
camkk2
ocular
och
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980054524.XA
Other languages
English (en)
Chinese (zh)
Inventor
斯科特·W·卡曾思
普里亚瑟姆·S·梅图
大卫·M·古登
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duke University
Original Assignee
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duke University filed Critical Duke University
Publication of CN112654353A publication Critical patent/CN112654353A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201980054524.XA 2018-08-20 2019-08-20 用于治疗眼部疾病的方法和药物成分 Pending CN112654353A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862719938P 2018-08-20 2018-08-20
US62/719,938 2018-08-20
PCT/US2019/047309 WO2020041344A1 (en) 2018-08-20 2019-08-20 Methods and compositions for drugs to treat ophthalmic diseases

Publications (1)

Publication Number Publication Date
CN112654353A true CN112654353A (zh) 2021-04-13

Family

ID=69591159

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980054524.XA Pending CN112654353A (zh) 2018-08-20 2019-08-20 用于治疗眼部疾病的方法和药物成分

Country Status (14)

Country Link
US (2) US12221447B2 (https=)
EP (1) EP3840745A4 (https=)
JP (1) JP2021534202A (https=)
KR (1) KR20210049857A (https=)
CN (1) CN112654353A (https=)
AU (1) AU2019326448A1 (https=)
BR (1) BR112021003189A2 (https=)
CA (1) CA3109809A1 (https=)
CO (1) CO2021003607A2 (https=)
IL (1) IL280952A (https=)
MX (1) MX2021002028A (https=)
SG (1) SG11202101522WA (https=)
TW (1) TW202021968A (https=)
WO (1) WO2020041344A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019326448A1 (en) 2018-08-20 2021-03-11 Duke University Methods and compositions for drugs to treat ophthalmic diseases
WO2024257328A1 (ja) * 2023-06-16 2024-12-19 千寿製薬株式会社 眼疾患モデル動物
JP7776899B1 (ja) * 2024-06-14 2025-11-27 株式会社坪田ラボ 局所投与用の重症眼表面疾患の処置剤

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003012516A (ja) * 2001-04-25 2003-01-15 Sumitomo Pharmaceut Co Ltd 新規なＣａＭＫＫ阻害剤
US9733406B2 (en) * 2006-01-13 2017-08-15 Crysoptix Kk Organic compound, anisotropic optical film and method of production thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0600763D0 (en) 2006-01-13 2006-02-22 Crysoptix Ltd 6, 7-dihydrobenzimidazo[1,2-C]quininazolin-6-one carboxylic acid, its esters and method of synthesis thereof
US8207185B2 (en) 2006-10-12 2012-06-26 Duke University CaMKKβ as a target for treating obesity
JP5464395B2 (ja) 2008-02-01 2014-04-09 大陽日酸株式会社 重水素化された芳香環又は複素環を有する化合物の製造方法
WO2009154754A2 (en) 2008-06-17 2009-12-23 Concert Pharmaceuticals, Inc. Synthesis of deuterated morpholine derivatives
WO2010033511A1 (en) 2008-09-16 2010-03-25 Concert Pharmaceuticals, Inc. Deuterated 2-amino-3-hydroxypropanoic acid derivatives
WO2012024255A2 (en) 2010-08-16 2012-02-23 Duke University Camkk-beta as a target for treating cancer
WO2012064618A1 (en) * 2010-11-09 2012-05-18 Crysoptix Kk Negative dispersion retardation plate and achromatic circular polarizer
CN103702961A (zh) 2011-05-23 2014-04-02 赛诺菲 含有n-烷基的氘代化合物的制备方法
CN104684555A (zh) 2012-09-18 2015-06-03 奥斯拜客斯制药有限公司 囊泡单胺转运体2的氘化苯并喹啉抑制剂的制剂药代动力学
EP2935251A1 (en) 2012-12-20 2015-10-28 Concert Pharmaceuticals Inc. Deuterated alk inhibitors
AU2014250762A1 (en) 2013-04-12 2015-10-29 Achillion Pharmaceuticals, Inc. Highly active nucleoside derivative for the treatment of HCV
RU2675270C2 (ru) 2013-10-17 2018-12-18 Вертекс Фармасьютикалз Инкорпорейтед Сокристаллы и содержащие их фармацевтические композиции
AU2019326448A1 (en) 2018-08-20 2021-03-11 Duke University Methods and compositions for drugs to treat ophthalmic diseases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003012516A (ja) * 2001-04-25 2003-01-15 Sumitomo Pharmaceut Co Ltd 新規なＣａＭＫＫ阻害剤
US9733406B2 (en) * 2006-01-13 2017-08-15 Crysoptix Kk Organic compound, anisotropic optical film and method of production thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HIROSHI TOKUMITSU: "STO-609, a Specific Inhibitor of the Ca2 /Calmodulin-dependent Protein Kinase Kinase" *

Also Published As

Publication number Publication date
WO2020041344A4 (en) 2020-03-26
WO2020041344A1 (en) 2020-02-27
KR20210049857A (ko) 2021-05-06
MX2021002028A (es) 2021-07-21
SG11202101522WA (en) 2021-03-30
CA3109809A1 (en) 2020-02-27
BR112021003189A2 (pt) 2021-05-11
EP3840745A1 (en) 2021-06-30
US12221447B2 (en) 2025-02-11
AU2019326448A1 (en) 2021-03-11
IL280952A (en) 2021-04-29
JP2021534202A (ja) 2021-12-09
EP3840745A4 (en) 2022-06-08
CO2021003607A2 (es) 2021-07-30
US20210198266A1 (en) 2021-07-01
US20250122209A1 (en) 2025-04-17
TW202021968A (zh) 2020-06-16

Similar Documents

Publication Publication Date Title
JP7332186B2 (ja) アルデヒドコンジュゲートおよびその使用
US20250122209A1 (en) Methods and compositions for drugs to treat ophthalmic diseases
US10077289B2 (en) Cyclosporins modified on the MeBmt sidechain by heterocyclic rings
KR101740076B1 (ko) Ｊａｋ 경로의 억제를 위한 조성물 및 방법
TW200916472A (en) Sirtuin modulating compounds
TW200918542A (en) Sirtuin modulating compounds
Wang et al. A new pharmacological effect of levornidazole: inhibition of NLRP3 inflammasome activation
JP2014530870A (ja) サーチュイン調節因子としての置換された二環式アザ複素環およびアナログ
WO2018053373A1 (en) Uses of satl-inducible kinase (sik) inhibitors for treating osteoporosis
JP2019523260A (ja) キラルペプチド
Pan et al. Baicalein—A potent pro-homeostatic regulator of microglia in retinal ischemic injury
JP2024133636A (ja) 皮膚エリテマトーデス及び扁平苔癬（ｌｐ）の治療のためのｊａｋ１阻害剤の使用
Hunziker et al. Synthesis, characterization, and in vivo evaluation of a novel potent autotaxin-inhibitor
US12233063B2 (en) Compositions and methods for treating eye disorders
US20230285556A1 (en) Methods and compositions for treating cancer
JP7848227B2 (ja) タンパク質キナーゼ阻害剤としてのヘテロ環化合物の新規塩およびこれらの用途
US20230263767A1 (en) Composition for preventing, alleviating, or treating inflammatory disease containing isookanin or salt thereof as active ingredient
US20030171379A1 (en) Methods of treating, preventing, or inhibiting inflammation with Mactanamide compounds
EP3525819A1 (en) Methods for treating ocular disease using inhibitors of csf-1r
WO2024029597A1 (ja) ＩＦＮ－γへ選択的に結合するＤＮＡオリゴヌクレオチドを含有するドライアイ治療薬
CN111432822A (zh) 包含腺苷衍生物的用于预防或治疗视网膜疾病或视神经疾病的药物组合物
US11701374B1 (en) 8-hydroxy quinoline derivatives for enhancing telomerase reverse transcriptase (TERT) expression
US20090221610A1 (en) Compositions and Methods for Treating Cognitive Disorders
US7074938B2 (en) Method for the synthesis of soritin compounds
Hunziker et al. Synthesis, Characterization, and in vivo Evaluation of a Novel Potent Autotaxin-Inhibitor. Front. Pharmacol. 12: 699535. doi: 10.3389/fphar. 2021.699535

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210413

WD01 Invention patent application deemed withdrawn after publication